How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

32,043 results for

Hypertension Evaluation History

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)

Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD) Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2017 Clinical Trials

22. Evaluation of a community-based hypertension improvement program (ComHIP) in Ghana: data from a baseline survey. (PubMed)

Evaluation of a community-based hypertension improvement program (ComHIP) in Ghana: data from a baseline survey. Ghana faces an increasing burden of non-communicable disease with rates of hypertension estimated as high as 36% in adults. Despite these high rates, hypertension control remains very poor in Ghana (4%). The current project aims to implement and evaluate a community-based programme to raise awareness, and to improve treatment and control of hypertension in the Eastern Region of Ghana (...) . In this paper, we present the findings of the baseline cross-sectional survey focusing on hypertension prevalence, awareness, treatment, and control.To evaluate the ComHIP project, a quasi-experimental design consisted of a before and after evaluations are being implemented in the intervention and comparison districts. A cohort study component is being implemented in the intervention district to assess hypertension control. Background anthropometric and clinical data collected as part of the baseline survey

Full Text available with Trip Pro

2017 BMC Public Health

23. Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins

Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins (NEW-HOPE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03198793 Recruitment Status : Completed First Posted : June 26, 2017 Last Update Posted : December 11, 2018 Sponsor: Quantum

2017 Clinical Trials

24. A Clinical Trial to Evaluate Safety and Efficacy of a Renal Denervation System in Treatment of Hypertension

A Clinical Trial to Evaluate Safety and Efficacy of a Renal Denervation System in Treatment of Hypertension A Clinical Trial to Evaluate Safety and Efficacy of a Renal Denervation System in Treatment of Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. A Clinical Trial to Evaluate Safety and Efficacy of a Renal Denervation System in Treatment of Hypertension The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2017 Clinical Trials

25. First-In-Human Study Evaluating a Novel Catheter Device in Subjects With Treatment-Resistant Hypertension

First-In-Human Study Evaluating a Novel Catheter Device in Subjects With Treatment-Resistant Hypertension First-In-Human Study Evaluating a Novel Catheter Device in Subjects With Treatment-Resistant Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. First-In-Human Study Evaluating a Novel Catheter Device in Subjects With Treatment-Resistant Hypertension The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03314012 Recruitment Status : Active, not recruiting First Posted : October 19, 2017 Last

2017 Clinical Trials

26. Evaluation of the Relationship between Serum 25-Hydroxy Vitamin D and Hypertension in Hamadan, Iran-A Case Control Study (PubMed)

to be required.This study was conducted to evaluate potential impact of serum vitamin D level on hypertension.This case-control study had 188 subjects including 55 cases suffering from hypertension and 133 controls with normal blood pressure in Hamadan, Iran. After taking the medical history and physical examination, 5 cc of their blood was taken to measure their serum 25-Hydroxyvitamin D [25(OH)D] level through ELISA test. Data analysis was done by version 16.0 of SPSS software and used independent sample t-test (...) Evaluation of the Relationship between Serum 25-Hydroxy Vitamin D and Hypertension in Hamadan, Iran-A Case Control Study Hypertension or high blood pressure is one of the main reasons of fatality in the world. The role of vitamin D in developing hypertension has not been proved yet. Some studies have shown positive correlation between low serum vitamin D level and hypertension. Due to this fact, recognising hypertension risk factors such as potential impact of low serum vitamin D level seems

Full Text available with Trip Pro

2017 Journal of clinical and diagnostic research : JCDR

27. ESC/ESH Management of Arterial Hypertension

hypertension3037 4.7.1 White-coat hypertension3037 4.7.2 Masked hypertension3038 4.8 Screening for the detection of hypertension3038 4.9 Confirming the diagnosis of hypertension3038 4.10 Clinical indications for out-of-office blood pressure measurements3038 4.11 Blood pressure during exercise and at high altitude3040 4.12 Central aortic pressure3040 5 Clinical evaluation and assessment of hypertension-mediated organ damage in patients with hypertension3041 5.1 Clinical evaluation3041 5.2 Medical history3041 (...) in Patients Living With Systolic Hypertension ACCORD Action to Control Cardiovascular Risk in Diabetes ACE Angiotensin-converting enzyme ACEi Angiotensin-converting enzyme inhibitor ACR Albumin:creatinine ratio ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicron – MR Controlled Evaluation AF Atrial fibrillation ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALTITUDE Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints

Full Text available with Trip Pro

2018 European Society of Cardiology

28. What could you do with 400 years of biological history on african americans? Evaluating the potential scientific benefit of systematic studies of dental and skeletal materials on African Americans from the 17th through 20th centuries (PubMed)

What could you do with 400 years of biological history on african americans? Evaluating the potential scientific benefit of systematic studies of dental and skeletal materials on African Americans from the 17th through 20th centuries How important is it to be able to reconstruct the lives of a highly diverse, historically recent macroethnic group over the course of 400 years? How many insights into human evolutionary biology and disease susceptibilities could be gained, even (...) history of this group and three case study applications are detailed for comparative computational systems biology studies of (1) hypertension, (2) the oral microbiome, and (3) mental health disorders.The 4Cs dataset is ideal for interdisciplinary "next generation" science research and these data represent a unique step toward the accumulation of historically contextualized Big Data on an underrepresented group known to have experienced differential survival over time. Am. J. Hum. Biol. 28:510-513

Full Text available with Trip Pro

2016 American Journal of Human Biology

29. Treatment of Hypertension in Association With Diabetes Mellitus

1998;338:645-52. Tatti P, Guarisco R, Pahor M, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:587-603. Pahor M, Applegate WB, Psaty BM, et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000;23:888-92. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular (...) Treatment of Hypertension in Association With Diabetes Mellitus XII. Treatment of Hypertension in Association With Diabetes Mellitus | Hypertension Canada Guidelines Subgroup Members: Richard E. Gilbert, MBBS PhD; Lawrence A. Leiter, MD; Charlotte Jones, PhD MD; Sheldon W. Tobe, MD MScCH; Vincent Woo, MD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C. Harris

2018 Hypertension Canada

30. Treatment of Hypertension in Association With Heart Failure

, the combination of valsartan and sacubitril is the only licensed ARNI product in Canada for the indication of heart failure and does not have a Health Canada indication for the treatment of hypertension . References Bourassa MG, Gurne O, Bangdiwala SL, et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993;22:14A-19A. Kostis JB. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens 1995;8:909 (...) Treatment of Hypertension in Association With Heart Failure VII. Treatment of Hypertension in Association With Heart Failure | Hypertension Canada Guidelines Subgroup Members: Simon W. Rabkin, MD; Gordon W. Moe, MD, MSc; Jonathan G. Howlett, MD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C. Harris, MD MHSc; Kerry McBrien, MD MPH; Sonia Butalia, BSc MD MSc

2018 Hypertension Canada

31. Treatment of Hypertension in Association With Ischemic Heart Disease

myocardial infarction. Systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202-12. Gustafsson F, Kober L, Torp-Pedersen C, Hildebrandt P, for the Trandolapril Cardiac Evaluation study. Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. J Hypertens 1998;16 (suppl 1):S65-S70. Kostis JB. The effect of enalapril on mortal and morbid (...) , Kober L, Torp-Pedersen C, Hildebrandt P for the Trandolapril Cardiac Evaluation study. Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. J Hypertens 1998;16 (suppl 1):S65-S70. Kostis JB. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens 1995;8:909-14. The Beta-Blocker Pooling Project Research Group

2018 Hypertension Canada

32. Global Vascular Protection Therapy for Adults with Hypertension Without Compelling Indications for Specific Agents

to 1.04) and less fatal and nonfatal stroke (RR 0.91; 95%CI, 0.75 to 1.09) with pravastatin, these differences did not reach statistical significance. The PROSPER trial was conducted in 5804 patients aged 70 years to 82 years (mean 75 years) with a history of vascular disease or risk factors (hypertension, smoking or diabetes mellitus) and total cholesterol concentration of 4.0 mmol/L to 9.0 mmol/L. Patients were randomly assigned to pravastatin 40 mg daily or to placebo, and after 3.2 years of follow (...) . In selected high-risk patients who might potentially benefit from lower BP targets, several major considerations should be made before implementing an intensive treatment strategy. First, risk evaluation should be primarily informed by the inclusion criteria used in the SPRINT trial (Table 5). Second, the risks and benefits of intervention should be carefully weighed, because patients with hypertension are at risk for adverse vascular events and also for adverse treatment effects. Caution should

2018 Hypertension Canada

33. Indications for Drug Therapy for Adults With Hypertension Without Compelling Indications for Specific Agents

had similar benefits with use of ramipril . PROGRESS randomly assigned 6105 patients with a history of stroke or transient ischemic attack to perindopril, with or without indapamide or placebo. With a mean BP at study entry of 157/89 mm Hg, active treatment lowered BP by 9/4 mm Hg and conferred a reduction in total vascular events of 26% . No strict recommendation has been made for the treatment of Stage 1 hypertension (BP 140–159/90–99 mm Hg) and no cardiovascular disease or risk factors (...) hypertension be treated? The different perspectives of Canadian family physicians and patients. CMAJ 2000;163:403-8. Steel N. Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey. BMJ 2000;320:1446-7. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:I45-53. PROGRESS Collaborative Group. Randomised trial

2018 Hypertension Canada

34. Prevention & Treatment of Hypertension - Health Behaviour Management

Institutes of Health guidelines. Arch Intern Med 2002;162:2074-9. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000;35:544-9. Lean MEJ, Han T S, Morrison C E. Waist circumference as a measure for indicating need for weight management. BMJ 1995;311:158-61. NHLBI Obesity Education Initiative. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults (...) -communicable disease intervention programme in Mauritius. BMJ 1995;311:1255-9. Friedman GD, Selby JV, Quesenberry CP Jr, Armstrong MA, Klatsky AL. Precursors of essential hypertension: body weight, alcohol and salt use, and parental history of hypertension. Prev Med 1988;17:387-402. D’Alonzo CA, Pell S. Cardiovascular disease among problem drinkers. J Occup Med 1968;10:344-50. Myrhed M. Alcohol consumption in relation to factors associated with ischemic heart disease. Acta Med Scand 1974;1:1-93. Carmelli D

2018 Hypertension Canada

35. Diagnosis & Assessment of Hypertension - Diagnosis

-normal (see thresholds outlined in ) annual follow-up is recommended (Grade C). If the visit 1 mean AOBP or non-AOBP is high (see thresholds outlined in ), a history and physical examination should be performed and, if clinically indicated, diagnostic tests to search for target organ damage (Supplemental ) and associated cardiovascular risk factors (Supplemental ) should be arranged within 2 visits. Exogenous factors that can induce or aggravate hypertension should be assessed and removed if possible (...) of progression to overt hypertension; and (b) a worse prognosis than patients with optimal blood pressure levels. Therefore, although antihypertensive therapy is not recommended, close surveillance in the form of annual blood pressure checks is recommended. 3. If the visit 1 mean OBPM or AOBP is high (see thresholds outlined in ), a history and physical examination should be performed and, if clinically indicated, diagnostic tests to search for target organ damage (Supplemental ) and associated

2018 Hypertension Canada

36. Lifestyle in progression from hypertensive disorders of pregnancy to chronic hypertension in Nurses' Health Study II: observational cohort study. (PubMed)

mass index, physical activity, adherence to the Dietary Approaches to Stop Hypertension (DASH) diet, and dietary sodium/potassium intake. Potential effect modification (interaction) between each lifestyle factor and previous HDP was evaluated with the relative excess risk due to interaction.Results 10% (n=5520) of women had a history of HDP at baseline. 13 971 cases of chronic hypertension occurred during 689 988 person years of follow-up. Being overweight or obese was the only lifestyle factor (...) Lifestyle in progression from hypertensive disorders of pregnancy to chronic hypertension in Nurses' Health Study II: observational cohort study. Objectives To study the association between lifestyle risk factors and chronic hypertension by history of hypertensive disorders of pregnancy (HDP: gestational hypertension and pre-eclampsia) and investigate the extent to which these risk factors modify the association between HDP and chronic hypertension.Design Prospective cohort study.Setting Nurses

Full Text available with Trip Pro

2017 BMJ

37. The Risk Factors That Predict Chronic Hypertension After Delivery in Women With a History of Hypertensive Disorders of Pregnancy. (PubMed)

The Risk Factors That Predict Chronic Hypertension After Delivery in Women With a History of Hypertensive Disorders of Pregnancy. Hypertensive disorders of pregnancy (HDP) is one of the most important lethal complications in pregnant mothers. It is also associated with the subsequent development of chronic hypertension. The objective of this study was to identify the clinical risk factors of postpartum chronic hypertension in women diagnosed with HDP.Six hundred patients as HDP, who diagnosed (...) and followed-up at least 6 month after delivery, were included in the study. We divided the included subjects in 2 groups based on the development of postpartum chronic hypertension: presenting with the chronic hypertension, "case group" (n = 41) and without chronic hypertension, "control group" (n = 559).Clinical and demographic factors were evaluated. By multiple regression analysis, early onset hypertension with end-organ dysfunction, smoking, higher prepregnancy body mass index (BMI), and comorbidities

Full Text available with Trip Pro

2015 Medicine

38. Ocular Hypertension

clinical management plan Reduction of IOP pharmacologically in patients at moderate or high risk of conversion to POAG Selective laser trabeculoplasty (SLT) Evidence base *GRADE: Grading of Recommendations Assessment, Development and Evaluation ( ) Sources of evidence Burr JM, Botello-Pinzon P, Takwoingi Y, Hernández R, Vazquez-Montes M, Elders A, et al. Surveillance for ocular hypertension: an evidence synthesis and economic evaluation. Health Technol Assess 2012;16(29) Vass C, Hirn C, Sycha T, Findl (...) Ocular Hypertension Ocular hypertension (OHT) submit The College submit You're here: Ocular hypertension (OHT) Ocular hypertension (OHT) The CMGs are guidelines on the diagnosis and management of a range of common and rare, but important, eye conditions that present with varying frequency in primary and first contact care. Share options Aetiology Ocular hypertension (OHT) is generally defined as consistently elevated intraocular pressure (IOP) (greater than 21mmHg [2 standard deviations above

2018 College of Optometrists

39. Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension

Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2016 Clinical Trials

40. Right Heart Dysfunction and Pulmonary Hypertension Evaluation in Airway Disease Using Cardiac Magnetic Resonance

Right Heart Dysfunction and Pulmonary Hypertension Evaluation in Airway Disease Using Cardiac Magnetic Resonance Right Heart Dysfunction and Pulmonary Hypertension Evaluation in Airway Disease Using Cardiac Magnetic Resonance - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Right Heart Dysfunction and Pulmonary Hypertension Evaluation in Airway Disease Using Cardiac Magnetic Resonance (RiPAIR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>